ABCELLERA BIOLOGICS INC. (ABCL)
AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026
AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026
📈 **POSITIVE** • Medium confidence analysis (76%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business